Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465235 | 0.89 | RECQL (0.55) | SMN1; SMN2RECQLL3MBTL1GAATSHR | |
| SCHEMBL6460158 | 0.87 | MEN1 (0.51) | SMN1; SMN2L3MBTL1TDP1KMT2APOLB | |
| SCHEMBL6468205 | 0.80 | KMT2A (0.52) | SMN1; SMN2RECQLL3MBTL1GAATSHR | |
| SCHEMBL11137902 | 0.79 | KMT2A (0.61) | RECQLL3MBTL1GAATSHRKMT2A | |
| SCHEMBL6466633 | 0.76 | ALDH1A1 (0.55) | SMN1; SMN2L3MBTL1GAATSHRTDP1 | |
| SCHEMBL6461792 | 0.75 | MEN1 (0.41) | L3MBTL1GAATDP1KMT2AMEN1 | |
| SCHEMBL23420325 | 0.73 | GAA (0.70) | SMN1; SMN2RECQLL3MBTL1GAATSHR | |
| SCHEMBL6465232 | 0.73 | TP53 (0.49) | SMN1; SMN2RECQLL3MBTL1GAATSHR | |
| SCHEMBL5534456 | 0.71 | KMT2A (0.66) | SMN1; SMN2L3MBTL1GAATSHRTDP1 | |
| SCHEMBL6465991 | 0.71 | LMNA (0.57) | SMN1; SMN2L3MBTL1GAATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005090299-A2 | CARBAMATES AS HIV ANTI-VIRAL AGENTS | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203176-A1 | Carbamates as HIV anti-viral agents | WYETH (US) | 2005-09-15 | — | — | US | claimed |
| WO-2005090299-A2 | CARBAMATES AS HIV ANTI-VIRAL AGENTS | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203176-A1 | Carbamates as HIV anti-viral agents | WYETH (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203176-A1 | Carbamates as HIV anti-viral agents | RNASEH1, CTSH, RNASE1 | SMN1; SMN2 4198/4885RECQL 1078/4885L3MBTL1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.